Abstract
The “cure” for the ever rising cost of in vitro ADME screening performed to support drug discovery may be readily at hand. Rationally putting into practice and real use existing in silico technology based on available ADME data can reduce costs in terms of volume of ADME screening and in some cases compound generation (potential compounds predicted to have poor attributes would not be synthesized). It is clear that in order for an in silico model to be successful; its development must require not only reliable and relevant data input, but also clarity and realistic expectations of its output. This work focuses on the development and application of an in silico passive apparent permeability (Papp) model, created with a specific purpose and end user in mind (i.e., medicinal chemist & pharmacokineticist working in early drug discovery). In addition, this work describes how this in silico model can be used in combination with experimental permeability screens such as PAMPA (Parallel Artificial Membrane Permeability Assay) & MDCK (Madin Darby Canine Kidney) cells to further guide drug discovery while enabling a resource sparing approach.
Keywords: ADME, Permeability, In silico, Caco-2, MDCK, Pampa, Computational
Letters in Drug Design & Discovery
Title: Moving in Silico Screening into Practice: A Minimalist Approach to Guide Permeability Screening!!
Volume: 3 Issue: 8
Author(s): Chad L. Stoner, Mathew Troutman, Hua Gao, Kjell Johnson, Charles Stankovic, Joanne Brodfuehrer, Eric Gifford and Man Chang
Affiliation:
Keywords: ADME, Permeability, In silico, Caco-2, MDCK, Pampa, Computational
Abstract: The “cure” for the ever rising cost of in vitro ADME screening performed to support drug discovery may be readily at hand. Rationally putting into practice and real use existing in silico technology based on available ADME data can reduce costs in terms of volume of ADME screening and in some cases compound generation (potential compounds predicted to have poor attributes would not be synthesized). It is clear that in order for an in silico model to be successful; its development must require not only reliable and relevant data input, but also clarity and realistic expectations of its output. This work focuses on the development and application of an in silico passive apparent permeability (Papp) model, created with a specific purpose and end user in mind (i.e., medicinal chemist & pharmacokineticist working in early drug discovery). In addition, this work describes how this in silico model can be used in combination with experimental permeability screens such as PAMPA (Parallel Artificial Membrane Permeability Assay) & MDCK (Madin Darby Canine Kidney) cells to further guide drug discovery while enabling a resource sparing approach.
Export Options
About this article
Cite this article as:
Stoner L. Chad, Troutman Mathew, Gao Hua, Johnson Kjell, Stankovic Charles, Brodfuehrer Joanne, Gifford Eric and Chang Man, Moving in Silico Screening into Practice: A Minimalist Approach to Guide Permeability Screening!!, Letters in Drug Design & Discovery 2006; 3 (8) . https://dx.doi.org/10.2174/157018006778194736
DOI https://dx.doi.org/10.2174/157018006778194736 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of COVID-19 on Gender Equality, Sexual and Reproductive Health Rights of Adolescent Girls and Young Women: A Narrative Review
Current Women`s Health Reviews Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Repositioning of Drugs as a Promising Strategy to Fight COVID-19
Coronaviruses Recent Applications of Bioinformatics in Target Identification and Drug Discovery for Alzheimer’s Disease
Current Topics in Medicinal Chemistry Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry The Severity of COVID-19 in Diabetes Patients
Current Diabetes Reviews Improved Prediction of Lysine Acetylation by Support Vector Machines
Protein & Peptide Letters Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
Current Gene Therapy Adhesion Molecules as Prognostic Biomarkers in Coronary Artery Disease
Current Topics in Medicinal Chemistry A Timeline of Ca<sup>2+</sup>/cAMP Signalling: From Basic Research to Potential Therapeutics for Dementia
Current Alzheimer Research Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Nanoparticle-based CRISPR/Cas Delivery: An Emerging Tactic for Cancer Therapy
Current Medicinal Chemistry Inhibitory Effects of Substituted Cinnamic Acid Esters on Mushroom Tyrosinase
Letters in Drug Design & Discovery Natural Substances and Semisynthetic Derivatives as Potential Alternative Products Against SARS-CoV-2
Mini-Reviews in Medicinal Chemistry <i>In Silico</i> Investigation of the SARS CoV2 Protease with Thymoquinone, the Major Constituent of <i>Nigella Sativa</i>
Current Drug Discovery Technologies Recent Progress in Structure Activity Relationship and Mechanistic Studies of Taxol Analogues
Mini-Reviews in Medicinal Chemistry Novel 4-bromo-2-(3-methyl-1-(substituted-phenylsulfonyl)-4,5-dihydro-1- H-pyrazol-5-yl)phenol Derivatives: Synthesis and Antibacterial Activity
Letters in Drug Design & Discovery An Outline of Contributing Vaccine Technologies for SARS CoV2 Advancing in Clinical and Preclinical Phase-Trials
Recent Patents on Biotechnology Recombinant Activated Factor VII as a General Haemostatic Agent:Evidence-Based Efficacy and Safety
Current Drug Safety